Which has better earnings and valuation, PFE or AMGN?

Pfizer has higher revenue and earnings than Amgen. Pfizer is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pfizer $62.58B 2.37 $7.77B $1.31 19.90 Amgen $37.22B 4.86 $7.71B $14.37 23.34

Is PFE or AMGN more profitable?

Amgen has a net margin of 20.96% compared to Pfizer's net margin of 11.83%. Amgen's return on equity of 137.41% beat Pfizer's return on equity. Company Net Margins Return on Equity Return on Assets Pfizer 11.83% 19.44% 8.41% Amgen 20.96% 137.41% 13.28%

Does the media favor PFE or AMGN?

In the previous week, Pfizer had 33 more articles in the media than Amgen. MarketBeat recorded 61 mentions for Pfizer and 28 mentions for Amgen. Amgen's average media sentiment score of 1.17 beat Pfizer's score of 0.97 indicating that Amgen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pfizer 40 Very Positive mention(s) 10 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 2 Very Negative mention(s) Positive Amgen 22 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Is PFE or GILD more profitable?

Gilead Sciences has a net margin of 30.99% compared to Pfizer's net margin of 11.83%. Gilead Sciences' return on equity of 48.19% beat Pfizer's return on equity. Company Net Margins Return on Equity Return on Assets Pfizer 11.83% 19.44% 8.41% Gilead Sciences 30.99% 48.19% 18.28%

Does the media favor PFE or GILD?

In the previous week, Pfizer had 16 more articles in the media than Gilead Sciences. MarketBeat recorded 61 mentions for Pfizer and 45 mentions for Gilead Sciences. Gilead Sciences' average media sentiment score of 1.05 beat Pfizer's score of 0.97 indicating that Gilead Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pfizer 40 Very Positive mention(s) 10 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 2 Very Negative mention(s) Positive Gilead Sciences 35 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Which has stronger earnings & valuation, PFE or MRNA?

Pfizer has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pfizer $62.58B 2.37 $7.77B $1.31 19.90 Moderna $1.94B 9.98 -$2.82B -$8.15 N/A

Is PFE or MRNA more profitable?

Pfizer has a net margin of 11.83% compared to Moderna's net margin of -143.55%. Pfizer's return on equity of 19.44% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets Pfizer 11.83% 19.44% 8.41% Moderna -143.55% -26.64% -19.32%

Does the media favor PFE or MRNA?

In the previous week, Pfizer had 54 more articles in the media than Moderna. MarketBeat recorded 61 mentions for Pfizer and 7 mentions for Moderna. Pfizer's average media sentiment score of 0.97 beat Moderna's score of -0.01 indicating that Pfizer is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pfizer 40 Very Positive mention(s) 10 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 2 Very Negative mention(s) Positive Moderna 3 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, PFE or NVAX?

Pfizer has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pfizer $62.58B 2.37 $7.77B $1.31 19.90 Novavax $1.12B 1.62 $440.30M -$0.58 N/A

Is PFE or NVAX more profitable?

Pfizer has a net margin of 11.83% compared to Novavax's net margin of -14.73%. Pfizer's return on equity of 19.44% beat Novavax's return on equity. Company Net Margins Return on Equity Return on Assets Pfizer 11.83% 19.44% 8.41% Novavax -14.73% -14.82% 1.23%

Does the media prefer PFE or NVAX?

In the previous week, Pfizer had 43 more articles in the media than Novavax. MarketBeat recorded 61 mentions for Pfizer and 18 mentions for Novavax. Pfizer's average media sentiment score of 0.97 beat Novavax's score of 0.61 indicating that Pfizer is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pfizer 40 Very Positive mention(s) 10 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 2 Very Negative mention(s) Positive Novavax 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Which has preferable valuation and earnings, ABBV or PFE?

Pfizer has higher revenue and earnings than AbbVie. Pfizer is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AbbVie $61.16B 6.23 $4.23B $2.03 106.25 Pfizer $62.58B 2.37 $7.77B $1.31 19.90

Is ABBV or PFE more profitable?

Pfizer has a net margin of 11.83% compared to AbbVie's net margin of 5.79%. Pfizer's return on equity of 19.44% beat AbbVie's return on equity. Company Net Margins Return on Equity Return on Assets AbbVie 5.79% -576.45% 13.39% Pfizer 11.83% 19.44% 8.41%

Does the media favor ABBV or PFE?

In the previous week, Pfizer had 7 more articles in the media than AbbVie. MarketBeat recorded 61 mentions for Pfizer and 54 mentions for AbbVie. AbbVie's average media sentiment score of 1.14 beat Pfizer's score of 0.97 indicating that AbbVie is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbbVie 37 Very Positive mention(s) 6 Positive mention(s) 7 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Positive Pfizer 40 Very Positive mention(s) 10 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 2 Very Negative mention(s) Positive

Pfizer (PFE) Competitors

$26.06 -0.08 (-0.29%)

As of 01:15 PM Eastern

Compare

PFE vs. AMGN, GILD, MRNA, NVAX, and ABBV

Should you buy Pfizer stock or one of its competitors? MarketBeat compares Pfizer with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pfizer include Amgen (AMGN), Gilead Sciences (GILD), Moderna (MRNA), Novavax (NVAX), and AbbVie (ABBV). These companies are all part of the "medical" sector.

How does Pfizer compare to Amgen?

Pfizer (NYSE:PFE) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, media sentiment, risk, institutional ownership and dividends.

Pfizer has higher revenue and earnings than Amgen. Pfizer is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pfizer	$62.58B	2.37	$7.77B	$1.31	19.90
Amgen	$37.22B	4.86	$7.71B	$14.37	23.34

In the previous week, Pfizer had 33 more articles in the media than Amgen. MarketBeat recorded 61 mentions for Pfizer and 28 mentions for Amgen. Amgen's average media sentiment score of 1.17 beat Pfizer's score of 0.97 indicating that Amgen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pfizer	40 Very Positive mention(s)	10 Positive mention(s)	6 Neutral mention(s)	3 Negative mention(s)	2 Very Negative mention(s)	Positive
Amgen	22 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

68.4% of Pfizer shares are owned by institutional investors. Comparatively, 76.5% of Amgen shares are owned by institutional investors. 0.6% of Pfizer shares are owned by insiders. Comparatively, 0.9% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 6.6%. Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 3.0%. Pfizer pays out 131.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Amgen pays out 70.1% of its earnings in the form of a dividend. Pfizer has increased its dividend for 16 consecutive years and Amgen has increased its dividend for 14 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Pfizer currently has a consensus target price of $28.82, indicating a potential upside of 10.58%. Amgen has a consensus target price of $355.19, indicating a potential upside of 5.90%. Given Pfizer's higher probable upside, equities research analysts plainly believe Pfizer is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pfizer	3 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.20
Amgen	2 Sell rating(s)	14 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.48

Amgen has a net margin of 20.96% compared to Pfizer's net margin of 11.83%. Amgen's return on equity of 137.41% beat Pfizer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pfizer	11.83%	19.44%	8.41%
Amgen	20.96%	137.41%	13.28%

Pfizer has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market. Comparatively, Amgen has a beta of 0.44, suggesting that its share price is 56% less volatile than the broader market.

Summary

Amgen beats Pfizer on 14 of the 20 factors compared between the two stocks.

How does Pfizer compare to Gilead Sciences?

Pfizer (NYSE:PFE) and Gilead Sciences (NASDAQ:GILD) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation, dividends and media sentiment.

Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 6.6%. Gilead Sciences pays an annual dividend of $3.28 per share and has a dividend yield of 2.4%. Pfizer pays out 131.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Gilead Sciences pays out 44.7% of its earnings in the form of a dividend. Pfizer has raised its dividend for 16 consecutive years and Gilead Sciences has raised its dividend for 10 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Gilead Sciences has a net margin of 30.99% compared to Pfizer's net margin of 11.83%. Gilead Sciences' return on equity of 48.19% beat Pfizer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pfizer	11.83%	19.44%	8.41%
Gilead Sciences	30.99%	48.19%	18.28%

Pfizer currently has a consensus price target of $28.82, indicating a potential upside of 10.58%. Gilead Sciences has a consensus price target of $156.93, indicating a potential upside of 16.42%. Given Gilead Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Gilead Sciences is more favorable than Pfizer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pfizer	3 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.20
Gilead Sciences	0 Sell rating(s)	4 Hold rating(s)	25 Buy rating(s)	0 Strong Buy rating(s)	2.86

In the previous week, Pfizer had 16 more articles in the media than Gilead Sciences. MarketBeat recorded 61 mentions for Pfizer and 45 mentions for Gilead Sciences. Gilead Sciences' average media sentiment score of 1.05 beat Pfizer's score of 0.97 indicating that Gilead Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pfizer	40 Very Positive mention(s)	10 Positive mention(s)	6 Neutral mention(s)	3 Negative mention(s)	2 Very Negative mention(s)	Positive
Gilead Sciences	35 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

68.4% of Pfizer shares are owned by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are owned by institutional investors. 0.6% of Pfizer shares are owned by company insiders. Comparatively, 0.3% of Gilead Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Pfizer has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market. Comparatively, Gilead Sciences has a beta of 0.31, indicating that its stock price is 69% less volatile than the broader market.

Gilead Sciences has lower revenue, but higher earnings than Pfizer. Gilead Sciences is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pfizer	$62.58B	2.37	$7.77B	$1.31	19.90
Gilead Sciences	$29.74B	5.63	$8.51B	$7.34	18.36

Summary

Gilead Sciences beats Pfizer on 12 of the 20 factors compared between the two stocks.

How does Pfizer compare to Moderna?

Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.

In the previous week, Pfizer had 54 more articles in the media than Moderna. MarketBeat recorded 61 mentions for Pfizer and 7 mentions for Moderna. Pfizer's average media sentiment score of 0.97 beat Moderna's score of -0.01 indicating that Pfizer is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pfizer	40 Very Positive mention(s)	10 Positive mention(s)	6 Neutral mention(s)	3 Negative mention(s)	2 Very Negative mention(s)	Positive
Moderna	3 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

68.4% of Pfizer shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 0.6% of Pfizer shares are held by company insiders. Comparatively, 10.8% of Moderna shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Pfizer currently has a consensus target price of $28.82, suggesting a potential upside of 10.58%. Moderna has a consensus target price of $35.73, suggesting a potential downside of 26.94%. Given Pfizer's stronger consensus rating and higher possible upside, research analysts clearly believe Pfizer is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pfizer	3 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.20
Moderna	5 Sell rating(s)	12 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.84

Pfizer has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pfizer	$62.58B	2.37	$7.77B	$1.31	19.90
Moderna	$1.94B	9.98	-$2.82B	-$8.15	N/A

Pfizer has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market. Comparatively, Moderna has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market.

Pfizer has a net margin of 11.83% compared to Moderna's net margin of -143.55%. Pfizer's return on equity of 19.44% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pfizer	11.83%	19.44%	8.41%
Moderna	-143.55%	-26.64%	-19.32%

Summary

Pfizer beats Moderna on 13 of the 17 factors compared between the two stocks.

How does Pfizer compare to Novavax?

Pfizer (NYSE:PFE) and Novavax (NASDAQ:NVAX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Pfizer has a net margin of 11.83% compared to Novavax's net margin of -14.73%. Pfizer's return on equity of 19.44% beat Novavax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pfizer	11.83%	19.44%	8.41%
Novavax	-14.73%	-14.82%	1.23%

Pfizer currently has a consensus price target of $28.82, indicating a potential upside of 10.58%. Novavax has a consensus price target of $12.13, indicating a potential upside of 9.48%. Given Pfizer's stronger consensus rating and higher possible upside, research analysts clearly believe Pfizer is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pfizer	3 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.20
Novavax	4 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.10

In the previous week, Pfizer had 43 more articles in the media than Novavax. MarketBeat recorded 61 mentions for Pfizer and 18 mentions for Novavax. Pfizer's average media sentiment score of 0.97 beat Novavax's score of 0.61 indicating that Pfizer is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pfizer	40 Very Positive mention(s)	10 Positive mention(s)	6 Neutral mention(s)	3 Negative mention(s)	2 Very Negative mention(s)	Positive
Novavax	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

68.4% of Pfizer shares are owned by institutional investors. Comparatively, 53.0% of Novavax shares are owned by institutional investors. 0.6% of Pfizer shares are owned by insiders. Comparatively, 1.0% of Novavax shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Pfizer has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market. Comparatively, Novavax has a beta of 2.37, indicating that its stock price is 137% more volatile than the broader market.

Pfizer has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pfizer	$62.58B	2.37	$7.77B	$1.31	19.90
Novavax	$1.12B	1.62	$440.30M	-$0.58	N/A

Summary

Pfizer beats Novavax on 14 of the 16 factors compared between the two stocks.

How does Pfizer compare to AbbVie?

AbbVie (NYSE:ABBV) and Pfizer (NYSE:PFE) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, media sentiment, institutional ownership and valuation.

In the previous week, Pfizer had 7 more articles in the media than AbbVie. MarketBeat recorded 61 mentions for Pfizer and 54 mentions for AbbVie. AbbVie's average media sentiment score of 1.14 beat Pfizer's score of 0.97 indicating that AbbVie is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbbVie	37 Very Positive mention(s)	6 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Positive
Pfizer	40 Very Positive mention(s)	10 Positive mention(s)	6 Neutral mention(s)	3 Negative mention(s)	2 Very Negative mention(s)	Positive

AbbVie presently has a consensus target price of $253.43, indicating a potential upside of 17.49%. Pfizer has a consensus target price of $28.82, indicating a potential upside of 10.58%. Given AbbVie's stronger consensus rating and higher probable upside, equities research analysts clearly believe AbbVie is more favorable than Pfizer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbbVie	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.88
Pfizer	3 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.20

Pfizer has higher revenue and earnings than AbbVie. Pfizer is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbbVie	$61.16B	6.23	$4.23B	$2.03	106.25
Pfizer	$62.58B	2.37	$7.77B	$1.31	19.90

70.2% of AbbVie shares are owned by institutional investors. Comparatively, 68.4% of Pfizer shares are owned by institutional investors. 0.1% of AbbVie shares are owned by insiders. Comparatively, 0.6% of Pfizer shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 3.2%. Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 6.6%. AbbVie pays out 340.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Pfizer pays out 131.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. AbbVie has raised its dividend for 53 consecutive years and Pfizer has raised its dividend for 16 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and lower payout ratio.

AbbVie has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market. Comparatively, Pfizer has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market.

Pfizer has a net margin of 11.83% compared to AbbVie's net margin of 5.79%. Pfizer's return on equity of 19.44% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbbVie	5.79%	-576.45%	13.39%
Pfizer	11.83%	19.44%	8.41%

Summary

AbbVie beats Pfizer on 11 of the 20 factors compared between the two stocks.

Get Pfizer News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PFE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PFE vs. The Competition

Export

Metric	Pfizer	Large Cap Pharma Industry	Medical Sector	NYSE Exchange
Market Cap	$148.57B	$307.25B	$6.42B	$23.17B
Dividend Yield	6.56%	2.76%	2.75%	4.07%
P/E Ratio	19.90	27.34	21.28	30.90
Price / Sales	2.37	5.06	558.91	24.62
Price / Cash	5.96	13.10	43.49	24.96
Price / Book	1.64	7.28	10.60	4.81
Net Income	$7.77B	$11.61B	$3.56B	$1.07B
7 Day Performance	0.56%	-1.15%	3.21%	1.35%
1 Month Performance	-0.77%	4.92%	6.51%	3.19%
1 Year Performance	11.20%	23.72%	36.74%	27.60%

Pfizer Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PFE Pfizer	3.9453 of 5 stars	$26.07 -0.3%	$28.82 +10.6%	+12.8%	$148.57B	$62.58B	19.90	75,000	Trending News Analyst Forecast
AMGN Amgen	4.2497 of 5 stars	$339.30 flat	$355.19 +4.7%	+20.9%	$183.12B	$36.75B	23.61	31,500	Positive News
GILD Gilead Sciences	4.7199 of 5 stars	$134.36 flat	$156.93 +16.8%	+25.6%	$166.82B	$29.44B	18.31	17,000
MRNA Moderna	1.4714 of 5 stars	$46.88 flat	$35.73 -23.8%	+82.6%	$18.60B	$1.94B	N/A	4,700	Analyst Forecast
NVAX Novavax	1.834 of 5 stars	$9.21 flat	$12.13 +31.7%	+49.1%	$1.51B	$1.12B	N/A	1,990	Options Volume Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:PFE) was last updated on 5/29/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pfizer (PFE) Competitors